Christopher Martin
Chairman bei Tokamak Energy Ltd.
Vermögen: 9 Mio $ am 31.03.2024
Profil
Christopher John Martin founded Sciona, Inc. in 2000, Paras Ltd.
in 1994, ADC Products (UK) Ltd.
in 2000, where he worked as Director from 2000 to 2016, ADC Therapeutics SA in 2011, where he worked as Non-Executive Director from 2022 to 2023, and Spirogen SARL in 2000, where he worked as Chief Executive Officer from 2000 to 2013.
Dr. Martin also founded Xenova Ltd.
Dr. Martin also currently works at Tokamak Energy Ltd., as Non-Executive Chairman, Tagworks Pharmaceuticals BV, as Chairman, Myricx Pharma Ltd., as Independent Chairman from 2023, Cascade Fund Management Ltd., as Director, Xenva Ltd., as Director from 1998, and Osivax SAS, as Director from 2023.
Dr. Martin also formerly worked at Allianz Technology Trust Plc, as Independent Non-Executive Director from 2010 to 2015, AstraZeneca PLC, as Member, and MedImmune Pharma BV, as Member-Management Board.
Dr. Martin received his doctorate degree from the University of Oxford, Masters Business Admin degree from International Institute for Management Development, and undergraduate degree from the University of Aston.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ADC THERAPEUTICS LTD
2,39% | 01.02.2023 | 1 968 743 ( 2,39% ) | 9 Mio $ | 31.03.2024 |
Aktive Positionen von Christopher Martin
| Unternehmen | Position | Beginn |
|---|---|---|
| Cascade Fund Management Ltd. | Director/Board Member | - |
Xenva Ltd.
 Xenva Ltd. Miscellaneous Commercial ServicesCommercial Services Xenva Ltd. provides boutique management services. The company was founded on June 19, 1997 and is headquartered in Hampshire, the United Kingdom. | Director/Board Member | 01.09.1998 |
Tokamak Energy Ltd.
 Tokamak Energy Ltd. BiotechnologyHealth Technology Tokamak Energy Ltd. provides medical and biotechnology services. It develops the potential to use fusion neutrons for a variety of applications from material treatments to medical applications or low cost hydrogen production. The company was founded by David Richard Kingham, Mikhail Gryaznevich and Alan Sykes in 2009 and is headquartered in Abingdon, the United Kingdom. | Chairman | - |
Osivax SAS
 Osivax SAS BiotechnologyHealth Technology Osivax SAS engages in the development of infectious diseases vaccines and immunotherapies based on oligoDOM? proprietary technology. It operates in the influenza vaccine "INFLUENZA - OVX836" business segment. The company was founded by Alexandre Le Vert, Florence Nicolas and Fergal Hill on May 15, 2017 and is headquartered in Lyon, France. | Director/Board Member | 23.02.2023 |
Tagworks Pharmaceuticals BV
 Tagworks Pharmaceuticals BV BiotechnologyHealth Technology Tagworks Pharmaceuticals BV is a Dutch precision therapy company that develops a new standard of care for patients suffering from severe diseases, including cancer. Tagworks Pharmaceuticals is based in and the Netherlands. The company leverages its technology platform, which is protected by a broad patent estate, to pioneer the click-to-release approach. Tagworks is developing a pipeline of click-cleavable therapies, including its lead program, TGW101, an antibody-drug conjugate targeting TAG72. The company's technology enables on-target activation of ADCs and immunomodulators, as well as off-target deactivation of radioimmunotherapies to enhance their therapeutic index. The company was founded in 2011 by Raffaella Rossin, Zach Taylor, Marc Robillard, and Marc Robillard has been the CEO since 2011. | Chairman | - |
Myricx Pharma Ltd.
 Myricx Pharma Ltd. Miscellaneous Commercial ServicesCommercial Services Myricx Pharma Ltd. engages in the development of novel proprietary inhibitors of human N-myristoyltransferases. The company was founded by Ed Tate, Roberto Solari, and Andrew Bell in 2019 and is headquartered in Stevenage, the United Kingdom. | Chairman | 15.11.2023 |
Ehemalige bekannte Positionen von Christopher Martin
| Unternehmen | Position | Ende |
|---|---|---|
| ADC THERAPEUTICS SA | Founder | 14.06.2023 |
ADC Products (UK) Ltd.
 ADC Products (UK) Ltd. Medical/Nursing ServicesHealth Services ADC Products (UK) Ltd. operates as a clinical stage biotechnology company. It develops pyrrolobenzodiazepines for antibody-drug conjugation. The company was founded in November 2000 and is headquartered in Reading, the United Kingdom. | Founder | 10.06.2016 |
| ALLIANZ TECHNOLOGY TRUST PLC | Director/Board Member | 15.07.2015 |
| ░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Christopher Martin
| University of Oxford | Doctorate Degree |
| International Institute for Management Development | Masters Business Admin |
| University of Aston | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| ADC THERAPEUTICS SA | Health Technology |
| Private Unternehmen | 13 |
|---|---|
Allianz Technology Trust Plc
 Allianz Technology Trust Plc Investment Trusts/Mutual FundsMiscellaneous Allianz Technology Trust Plc operates as a closed-end investment fund, which invests principally in the equity securities of quoted technology companies with long-term capital growth. It seeks to hold companies that creates shareholder value through the introduction of a new product or new technology. The company was founded on October 18, 1995 and is headquartered in London, the United Kingdom. | Miscellaneous |
Sciona, Inc.
 Sciona, Inc. Pharmaceuticals: MajorHealth Technology Sciona, Inc. provides health and nutrition recommendations. It researches and develops DNA screens for common gene variants that affect an individual's response to food, medications and the environment. These genetic screens serve as the basis for providing personalized advice to consumers. The company was founded by Rosalynn Gill-Garrison and Gareth Roberts on June 8, 2000 and is headquartered in Boulder, CO. | Health Technology |
| Cascade Fund Management Ltd. | |
Paras Ltd.
 Paras Ltd. Miscellaneous Commercial ServicesCommercial Services Paras Ltd. provides information management and strategy consultancy services to the energy sector. The company was founded by Hamish Angus Munro Wilson in 1993 and is headquartered in Abingdon, the United Kingdom. | Commercial Services |
ADC Products (UK) Ltd.
ADC Products (UK) Ltd. Medical/Nursing ServicesHealth Services ADC Products (UK) Ltd. operates as a clinical stage biotechnology company. It develops pyrrolobenzodiazepines for antibody-drug conjugation. The company was founded in November 2000 and is headquartered in Reading, the United Kingdom. | Health Services |
Xenva Ltd.
Xenva Ltd. Miscellaneous Commercial ServicesCommercial Services Xenva Ltd. provides boutique management services. The company was founded on June 19, 1997 and is headquartered in Hampshire, the United Kingdom. | Commercial Services |
MedImmune Pharma BV
 MedImmune Pharma BV BiotechnologyHealth Technology MedImmune Pharma BV develops, manufactures and markets formulations for use in immunization programs. It specializes in the production of a vaccine called Amifostine. The company was founded in 1993 and is headquartered in Nijmegen, Belgium. | Health Technology |
Tokamak Energy Ltd.
Tokamak Energy Ltd. BiotechnologyHealth Technology Tokamak Energy Ltd. provides medical and biotechnology services. It develops the potential to use fusion neutrons for a variety of applications from material treatments to medical applications or low cost hydrogen production. The company was founded by David Richard Kingham, Mikhail Gryaznevich and Alan Sykes in 2009 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Spirogen SARL
 Spirogen SARL Pharmaceuticals: MajorHealth Technology Spirogen SARL is a Swiss company. 'The private company is based in Lausanne, Switzerland. The company was founded by Christopher John Martin. | Health Technology |
Osivax SAS
Osivax SAS BiotechnologyHealth Technology Osivax SAS engages in the development of infectious diseases vaccines and immunotherapies based on oligoDOM? proprietary technology. It operates in the influenza vaccine "INFLUENZA - OVX836" business segment. The company was founded by Alexandre Le Vert, Florence Nicolas and Fergal Hill on May 15, 2017 and is headquartered in Lyon, France. | Health Technology |
Tagworks Pharmaceuticals BV
Tagworks Pharmaceuticals BV BiotechnologyHealth Technology Tagworks Pharmaceuticals BV is a Dutch precision therapy company that develops a new standard of care for patients suffering from severe diseases, including cancer. Tagworks Pharmaceuticals is based in and the Netherlands. The company leverages its technology platform, which is protected by a broad patent estate, to pioneer the click-to-release approach. Tagworks is developing a pipeline of click-cleavable therapies, including its lead program, TGW101, an antibody-drug conjugate targeting TAG72. The company's technology enables on-target activation of ADCs and immunomodulators, as well as off-target deactivation of radioimmunotherapies to enhance their therapeutic index. The company was founded in 2011 by Raffaella Rossin, Zach Taylor, Marc Robillard, and Marc Robillard has been the CEO since 2011. | Health Technology |
Myricx Pharma Ltd.
Myricx Pharma Ltd. Miscellaneous Commercial ServicesCommercial Services Myricx Pharma Ltd. engages in the development of novel proprietary inhibitors of human N-myristoyltransferases. The company was founded by Ed Tate, Roberto Solari, and Andrew Bell in 2019 and is headquartered in Stevenage, the United Kingdom. | Commercial Services |
| Xenova Ltd. |
